News

Video

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Patients With Poor Prognosis Hepatocellular Carcinoma

Author(s):

William P. Harris, MD

William Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.

Related Videos
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
DB-12
5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
RMC-9805
LGSOC 2024
Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung
Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 primary results
Richard Kim, MD, Moffitt Cancer Center
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Related Content
Penpulimab Plus Anlotinib for Advanced HCC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 26th 2024

China’s NMPA Accepts sNDA for Penpulimab Plus Anlotinib for Advanced HCC

Alan P. Venook, MD
November 25th 2024

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center
November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Chris Galloway, MD
October 21st 2024

FDA Accepts NDA Resubmission for First-Line Rivoceranib/Camrelizumab Combo in Unresectable HCC

Saeho Chong, PhD, chief executive officer, Elevar Therapeutics
September 23rd 2024

NDA Resubmitted for Camrelizumab Plus Rivoceranib in Unresectable HCC